Neurotype Inc.
Minneapolis
About Neurotype Inc.
Medical device focused on treating brain circuits that underlie drug craving caused by environmental triggers for drug use addiction healthcare. People in recovery are constantly reminded of drug use by environmental cues (people, places, things linked to prior drug use), remaining a persistent risk for relapse, overdoses, and diminished life quality. The NeuromarkR platform (headset+software) measures brain signatures of drug craving not currently addressed in gold standard addiction healthcare. NeuromarkR enables targeted interventions to address triggers for craving by tailored psychotherapy that uses Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Treatment (MBT) strategies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.2M
- Funding stage: Seed
- Last round: Seed (Sep 2023)
- Website: neurotype.io
- Phone: 651-431-0573
Industries & Categories
Health Care, Information Technology, Medical Device, Neuroscience, Software
Social Profiles
Canonical: https://fsome.com/organization/neurotype-inc-106293 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.